scholarly journals Dendritic cell maturation in the corneal epithelium with onset of type 2 diabetes is associated with tumor necrosis factor receptor superfamily member 9

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Neil S. Lagali ◽  
Reza A. Badian ◽  
Xu Liu ◽  
Tobias R. Feldreich ◽  
Johan Ärnlöv ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Dendritic Cell ◽  
Tumor Necrosis Factor ◽  
Corneal Epithelium ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Receptor ◽  
Low Grade ◽  
Antigen Presenting ◽  
Necrosis Factor

AbstractType 2 diabetes mellitus is characterized by a low-grade inflammation; however, mechanisms leading to this inflammation in specific tissues are not well understood. The eye can be affected by diabetes; thus, we hypothesized that inflammatory changes in the eye may parallel the inflammation that develops with diabetes. Here, we developed a non-invasive means to monitor the status of inflammatory dendritic cell (DC) subsets in the corneal epithelium as a potential biomarker for the onset of inflammation in type 2 diabetes. In an age-matched cohort of 81 individuals with normal and impaired glucose tolerance and type 2 diabetes, DCs were quantified from wide-area maps of the corneal epithelial sub-basal plexus, obtained using clinical in vivo confocal microscopy (IVCM). With the onset of diabetes, the proportion of mature, antigen-presenting DCs increased and became organized in clusters. Out of 92 plasma proteins analysed in the cohort, tumor necrosis factor receptor super family member 9 (TNFRSF9) was associated with the observed maturation of DCs from an immature to mature antigen-presenting phenotype. A low-grade ocular surface inflammation observed in this study, where resident immature dendritic cells are transformed into mature antigen-presenting cells in the corneal epithelium, is a process putatively associated with TNFRSF9 signalling and may occur early in the development of type 2 diabetes. IVCM enables this process to be monitored non-invasively in the eye.

scholarly journals Relationship between serum tumor necrosis factor receptor-2 concentration and periodontal destruction in patients with type 2 diabetes: Cross-sectional study

2016 ◽  
Vol 144 (5-6) ◽  
pp. 266-272 ◽  
Author(s):  
Sanja Matic-Petrovic ◽  
Ana Pucar ◽  
Aleksandra Jotic ◽  
Biljana Milicic ◽  
Jelena Arambasic-Jovanovic ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Tumor Necrosis Factor ◽  
Surface Area ◽  
Tumor Necrosis ◽  
Periodontal Diseases ◽  
Tumor Necrosis Factor Receptor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Periodontal Destruction ◽  
Necrosis Factor

Introduction. The role of tumor necrosis factor-? (TNF?) is well documented in pathogenesis of chronic periodontitis (CP) and type 2 diabetes (T2D). Considering short half-life of TNF?, tumor necrosis factor receptor-2 (TNFR2) is used as prosperous surrogate marker of TNF? activity. Objective. The aim was to detect TNFR2 serum concentration and correlate it with periodontal destruction in patients with diagnosed T2D and nondiabetics. Methods. The study included 85 patients divided into three groups: T2D + CP (group T2D, n = 34); nondiabetics + CP (Group PD, n = 27); and healthy controls (group HC, n = 24). T2D was diagnosed according to WHO criteria (2013) and periodontitis was diagnosed using International Workshop for a Classification of Periodontal Diseases and Conditions criteria (1999). TNFR2 level was measured by enzyme-linked immunosorbent assay (ELISA). Results. There was no difference in TNFR2 level among the groups (Kruskal-Wallis, p = 0.482). Significant correlation (Pearson?s correlation coefficient) was observed between clinical attachment loss (CAL) and TNFR2 concentration in PD group (rp = -0.460, p = 0.016). In T2D group, correlations were observed between TNFR2 concentration and CAL (rp = 0.363, p = 0.005) and periodontal inflamed surface area (PISA) (rp = 0.345, p = 0.046) and periodontal epithelial surface area (PESA) (rp = 0.578, p = 0.000). Conclusion. Higher concentration of TNFR2 was associated with higher CAL, PESA, and PISA scores in T2D group. Contrary to that, nondiabetics with higher values of CAL exhibited lower concentration of TNFR2, presenting potential protective effect on periodontal destruction. These results imply that diabetes may alter TNFR2 secretion originated from periodontium.

scholarly journals Circulating levels of soluble tumor necrosis factor receptor 2 are associated with progressive diabetic kidney disease in patients with type 2 diabetes mellitus

2020 ◽  
Author(s):  
Tsung-Hui Wu ◽  
Li-Hsin Chang ◽  
Chia-Huei Chu ◽  
Chii-Min Hwu ◽  
Harn-Shen Chen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Tumor Necrosis Factor ◽  
Kidney Disease ◽  
Tumor Necrosis ◽  
Diabetic Kidney Disease ◽  
Tumor Necrosis Factor Receptor ◽  
Renal Outcomes ◽  
Circulating Levels ◽  
Necrosis Factor

Abstract Background Chronic low-grade inflammation is considered one of the major mechanisms for the progression of diabetic kidney disease. We investigated the prognostic value of circulating soluble tumor necrosis factor receptor 2 (sTNFR2) for early nephropathy in patients with type 2 diabetes. Materials and methods A total of 346 patients with type 2 diabetes and an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2 were followed up for a median of 4 years. Renal outcomes were defined as a composite of either or both a > 30% decline in the eGFR and/or albuminuria stage progression determined with consecutive tests. Results Sixty-nine patients developed renal composite events. Serum concentrations of sTNFR2 were strongly associated with the risk of renal function decline and progressive changes in albuminuria. Through a receiver operating characteristic curve analysis, a serum sTNFR2 level of 1.608 ng/mL was adopted as the discriminator value for predicting renal outcomes (area under the curve 0.61, 95% confidence interval 0.54–0.68, p = 0.005), yielding a sensitivity of 73.9% and a specificity of 48.7%. The association of sTNFR2 levels ≥ 1.608 ng/mL to renal outcomes was significant after adjusting for relevant variables (hazard ratio 1.95, 95% confidence interval 1.01–3.74, p = 0.046) and remained consistent across subgroups stratified by age, sex, systolic blood pressure, eGFR, albuminuria, and the use of renin-angiotensin system blockers. Conclusions Higher circulating levels of sTNFR2 are independently associated with an eGFR decline and progressive albuminuria in patients with type 2 diabetes.

SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR TYPE 1 LEVELS EXHIBIT A STRONGER ASSOCIATION WITH RENAL OUTCOMES THAN TRADITIONAL RISK FACTORS IN CHINESE SUBJECTS WITH TYPE 2 DIABETES MELLITUS

2020 ◽  
Vol 26 (10) ◽  
pp. 1115-1124
Author(s):  
Li-Hsin Chang ◽  
Chii-Min Hwu ◽  
Yi-Chun Lin ◽  
Chin-Chou Huang ◽  
Justin G.S. Won ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Diabetic Kidney Disease ◽  
Tumor Necrosis Factor Receptor ◽  
Receptor Type ◽  
Renal Outcomes ◽  
Necrosis Factor

Objective: Associations between albuminuria and renal outcomes are inconsistent in patients with type 2 diabetes (T2D). Soluble tumor necrosis factor receptor type 1 (sTNFR1) is involved in declined kidney function and poor renal outcomes but this has not been confirmed among Chinese T2D patients. This study aimed to examine the association of sTNFR1 and renal outcomes in a cohort of these patients. Methods: Two hundred and eighty-three Chinese T2D patients were enrolled in a prospective observational study which excluded individuals with estimated glomerular filtration rates (eGFR) <30 mL/min/1.73m2. Composite renal outcomes included either or both a >30% decline in eGFR and worsening albuminuria from consecutive tests of blood/urine during a 3.5-year follow-up. Results: Higher sTNFR1 levels were associated with impaired renal outcomes. sTNFR1 levels of ≥979 pg/mL yielded the most sensitivity and specific predictions of renal outcomes according to the receiver operating curve (area under the curve 0.68, P<.001; sensitivity 78.3%, specificity 48.9%). Renal events occurred more frequently in subjects with sTNFR1 ≥979 pg/mL than in others (sTNFR1 <979 pg/mL; 29% versus 10%; P<.001 by log-rank test). The association between sTNFR1 ≥979 pg/mL and renal outcomes remained significant after adjustment for relevant covariates (adjusted hazard ratio 2.43, 95% confidence interval 1.18 to 5.02; P = .01) and consistent across subgroups stratified by age, sex, blood pressure, eGFR, albuminuria, and the use of renin-angiotensin system inhibitors. Conclusion: Increased sTNFR1 levels were associated with renal outcomes in Chinese T2D subjects, making sTNFR1 a potential biomarker in diabetic kidney disease. Abbreviations: BMI = body mass index; CI = confidence interval; DKD = diabetic kidney disease; eGFR = estimated glomerular filtration rate; GLP-1a = glucagon-like peptide-1 agonist; HR = hazard ratio; RAS = reninangiotensin system; ROC = receiver operating characteristic; SGLT2i = inhibitors of the sodium glucose cotransporter; sTNFR1 = soluble tumor necrosis factor receptor type 1; T2D = type 2 diabetes; UACR = urinary albumin-creatinine ratio

Function and Regulation of Tumor Necrosis Factor Receptor Type 2

2004 ◽  
Vol 11 (16) ◽  
pp. 2205-2212 ◽  
Author(s):  
I. Carpentier ◽  
B. Coornaert ◽  
R. Beyaert
Keyword(s):  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Receptor ◽  
Receptor Type ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document